Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Bas...( Results from a 24-week multi-center r...),Health

Results from a 24-week multi-center, randomized, open-label study presented

at ADA 2008

SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced data showing that the use of mealtime SYMLIN(R) (pramlintide acetate) injection with basal insulin therapy for 24 weeks resulted in more patients achieving diabetes treatment goals of improved glucose control without weight gain or hypoglycemia compared to the use of rapid-acting insulin (RAI) with basal insulin in patients with type 2 diabetes. The results were detailed in an oral presentation at the American Diabetes Association's (ADA) 68th Annual Scientific Sessions in San Francisco.

"These findings are promising because they suggest that treating a deficiency of the hormone amylin in type 2 diabetes can have a beneficial effect on glucose control even when mealtime insulin is not used," said Matthew Riddle, M.D., Professor of Medicine and Head of the Section of Diabetes, Division of Endocrinology at Oregon Health Sciences University and clinical trial investigator. "The effect of SYMLIN was similar to that of mealtime rapid-acting insulin when either was added to basal insulin treatment in this study, with SYMLIN use resulting in no weight gain and less hypoglycemia."

The study was designed to demonstrate improvement in pre-defined comprehensive diabetes treatment goals that included achieving a target A1C and experiencing no weight gain or episodes of severe hypoglycemia. Among those treated with mealtime SYMLIN, 1 in 3 achieved this composite set of goals while only 1 in 10 patients treated with RAI achieved the same results (30 percent vs. 11 percent; P<0.05). Mild or moderate hypoglycemi
'/>"/>